5 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 47.2% per year over the past 4 years.
Operating margin has contracted, at -136.9% in the latest year.
Financial health
Total debt has grown faster than revenue (53.1% vs 47.2% per year).
Operating income covered interest expense -10.7× in the latest year, down from -2.9× 4 years ago.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$235M
-$248M
54.2%
-136.9%
-17.4%
-9.0%
—
—
$45M
2024
$162M
$331M
46.6%
283.6%
33.9%
21.8%
—
$301M
$85M
2023
—
$22M
—
—
4.5%
3.0%
—
$187M
$31M
2023
$82M
-$66M
47.5%
-83.6%
-239.7%
-34.5%
—
$151M
$10M
2022
$74M
-$32M
65.0%
-26.9%
-36.3%
-13.0%
—
$128M
$21M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Jun '26
$75M
-$150M
64.1%
-275.4%
-10.4%
-1.5%
—
—
$234M
Mar '26
$71M
-$220M
64.0%
-521.5%
-15.9%
-8.4%
—
—
$160M
Dec '25
$88M
-$280M
60.4%
-491.4%
-19.7%
-10.2%
—
—
$45M
Sep '25
$84M
$50M
61.3%
87.0%
3.5%
1.9%
—
—
$33M
Jun '25
$41M
$137M
47.3%
454.9%
10.8%
6.8%
—
—
$216M
Mar '25
$22M
-$134M
14.5%
-676.8%
-13.9%
-8.5%
—
—
$108M
Dec '24
$32M
$152M
35.9%
889.5%
15.6%
10.0%
—
$301M
$85M
Sep '24
$44M
$647000
59.9%
-3.6%
0.1%
0.1%
—
$297M
—
Jun '24
$35M
-$72M
41.4%
-246.2%
-10.9%
-6.6%
—
$329M
—
Mar '24
$52M
$251M
45.6%
515.8%
34.3%
25.1%
—
$178M
$12M
Dec '23
—
$11M
—
—
2.2%
1.4%
—
$187M
$31M
Sep '23
$22M
-$4M
37.7%
-3.1%
-18.7%
-2.4%
—
—
—
Jun '23
$21M
-$2M
41.6%
4.6%
-6.2%
-0.9%
—
$151M
$10M
Mar '23
$16M
$17M
45.6%
-11.3%
60.3%
—
—
—
—
Sep '22
—
-$560000
—
—
-0.6%
—
—
—
—
Valuation over time
How the market has priced HUT against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 42.0× (Jan '24) to 16.8× (Nov '25).
The price-to-sales ratio has risen from 3.1× (Mar '23) to 46.1× (Sep '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Frequently asked questions
Is HUT growing its revenue and profit?
Over the past 4 years, Hut 8's revenue has grown 47.2% per year. These are computed facts, not advice.
How much debt does HUT have?
As of FY2025, Hut 8 reported — of total debt against $45M of cash; operating income covered interest expense -10.7×.
What is HUT's profit margin?
In FY2025, gross margin was 54.2%, operating margin -136.9%, and net margin -105.5%.
What is HUT's P/E ratio?
As of Sep '26, Hut 8 traded at a price-to-earnings ratio of about 16.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.